Latham Advises Novo Holdings on Investment in SCHOTT Poonawalla

Latham & Watkins has advised Novo Holdings on its investment in SCHOTT Poonawalla, India’s leading provider of high-quality drug containment and delivery solutions for injectable pharmaceuticals, alongside TPG Growth, the middle market and growth equity platform of global alternative asset management firm TPG.

SCHOTT Poonawalla is a joint venture between SCHOTT Pharma AG and the Serum Institute of India and is recognized as India’s foremost manufacturer of injectable-focused primary packaging, offering a full range of products including ampoules, vials, cartridges, and prefilled syringes.

The investment underscores Novo Holdings’ commitment to building long-term partnerships with differentiated healthcare platforms in Asia, and marks the company’s first investment in the Medtech manufacturing space in India.

The Latham team was led by London corporate partners Robbie McLaren and Clare Scott, with counsel Medha Marathe and associates Devdeep Ghosh, Hadi Najem, and Kennan Castel-Fodor.